E2F1 and benign prostatic hyperplasia: In accordance with this, 6SL significantly reduced the overexpression of pRb and E2F1, suggesting that the therapeutic effects of 6SL on BPH may be dependent on AR-related E2F1 regulation inhibition (Figure 3B).